A Phase 2 interventional study of EGP-437 1.6 mA-min at 0.4 with EyeGate® II System and EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System in Uveitis, Anterior, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-08-31.
Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Uveitis, Anterior with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Uveitis, Anterior · United States.
Among the 30 studies in Uveitis, Anterior with a site in United States, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2008, is one of 6 in phase 2, and was the 5th registered.
56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.
Browse Uveitis, Anterior studies →5 of the 30 studies in Uveitis, Anterior with a site in United States are open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 5–85 · Healthy volunteers
Massachusetts Eye Research and Surgery Institution · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States, Taiwan, Thailand
Ages 18+ · Healthy volunteers
Nisha Acharya · Sites in United States, Italy, United Kingdom
Ages 2+
CARE ARTHRITIS LTD. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Uveitis, Anterior studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 12 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.
Median enrollment 40 across the 27 interventional studies, 50 across the 3 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
Eyegate Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Eyegate Pharmaceuticals, Inc. has 3 studies filed under Uveitis, Anterior — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis, Anterior with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285070Novaliq GmbHTacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | 2026-12 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Uveitis, Anterior with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
This is a randomized, double-masked, parallel group, dose-comparison, exploratory study of four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients with non-infectious anterior segment uveitis. The current study will evaluate the safety, tolerability, and efficacy of this technology at the four dose levels to determine a safe effective dose appropriate for future trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Drug page: Dexamethasone phosphate
Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
Also known as: Dexamethasone Phosphate Ophthalmic Solution
Drug page: Dexamethasone phosphate
Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
Also known as: Dexamethasone Phosphate Ophthalmic Solution
Drug page: Dexamethasone phosphate
Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
Also known as: Dexamethasone Phosphate Ophthalmic Solution
Drug page: Dexamethasone phosphate
Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
Also known as: Dexamethasone Phosphate Ophthalmic Solution
Proportion of subjects with an ACC score of zero at Days 14 and 28
Proportion of subjects with an anterior chamber cell (ACC) score of zero at Days 14 and 28
Time frame: Prospective study, subjects followed for 28 days
Time to ACC score of zero
Time to anterior chamber cell score of zero
Time frame: Prospective study, subjects followed for 28 days
Proportion of subjects with a reduction of one full ACC score or more from baseline at Day 28
Proportion of subjects with a reduction of one full anterior chamber cell score or more (≥ 0.5 decrease) from baseline at Day 28
Time frame: Prospective study, subjects followed for 28 days
Change from baseline in ACC score at Day 28
Change from baseline in anterior chamber cell score at Day 28
Time frame: Prospective study, subjects followed for 28 days
Treatment emergent adverse events
Treatment emergent adverse events
Time frame: Prospective study, subjects followed for 28 days
The record gives a start of Jun 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone phosphate
Eyegate Pharmaceuticals, Inc.